LITS vs REGN · $29.7M cap vs P/E 14, rev $14.34B
Lite Strategy, Inc. (LITS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Lite Strategy, Inc. (LITS) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported LITS revenue for 2025-06-30 was $0. Net income was -$15.9M. Revenue was down 100.0% from 2024-06-30 to 2025-06-30. LITS currently screens at market cap $29.7M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
LITS currently screens at market cap $29.7M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the LITS and REGN stock pages for the full models.
Not investment advice.